<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1134-8046</journal-id>
<journal-title><![CDATA[Revista de la Sociedad Española del Dolor]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Soc. Esp. Dolor]]></abbrev-journal-title>
<issn>1134-8046</issn>
<publisher>
<publisher-name><![CDATA[Inspira Network Group, S.L ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1134-80462018000200086</article-id>
<article-id pub-id-type="doi">10.20986/resed.2017.3594/2017</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficacia de medicamentos antihomotóxicos en el tratamiento del síndrome miofascial cervical y de cintura escapular: estudio comparativo versus toxina botulínica tipo A]]></article-title>
<article-title xml:lang="en"><![CDATA[Efficacy of antihomotoxic medicine in treatment of cervical miofascial síndrome and shoulder girdle: comparative study versus botulinum toxin type A]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garnica-Téllez]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arias-Vázquez]]></surname>
<given-names><![CDATA[P.I.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Wakamatzu]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,UMF 34 IMSS. Tulancingo Servicio de Medicina Física y Rehabilitación ]]></institution>
<addr-line><![CDATA[Hidalgo ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Juárez Autónoma de Tabasco Departamento de Rehabilitación ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Clínica de Rehabilitación "ARUKU"  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<volume>25</volume>
<numero>2</numero>
<fpage>86</fpage>
<lpage>93</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1134-80462018000200086&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1134-80462018000200086&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1134-80462018000200086&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  El síndrome de dolor miofascial es una causa común de dolor muscular en región cervical y cintura escapular. El tratamiento ha incluido medios conservadores y procedimientos invasivos; los medios conservadores incluyen fármacos, modalidades de terapia física, masaje y ejercicio terapéutico; los procedimientos invasivos incluyen punción seca e inyecciones en los puntos gatillo de diversas sustancias como toxina botulínica tipo A, esteroides, anestésicos locales e incluso se ha reportado eficacia con la inyección de medicamentos homeopáticos complejos conocidos como medicamentos antihomotóxicos.  Objetivo:  Comparar la eficacia de las inyecciones intramusculares en puntos gatillo, usando toxina botulínica tipo A versus medicamentos antihomotóxicos.  Materiales y métodos:  Se realizó un estudio experimental, longitudinal, prospectivo, aleatorizado y ciego, tipo ensayo clínico controlado, que incluyó 31 pacientes con diagnóstico de síndrome miofascial de región cervical y cintura escapular, divididos en 3 grupos; cada grupo recibió inyecciones intramusculares en puntos gatillo. Un grupo fue tratado con toxina botulínica tipo A con una dosis de 10 U por punto gatillo, otro grupo se trató con una combinación de medicamentos antihomotóxicos que incluyó una mezcla de Traumeel(r) S, Spascupreel(r), Gels Homaccord(r) y Lymphomyosot(r) a razón de 1 ml de esta combinación por punto gatillo; el tercer grupo recibió tratamiento placebo con solución salina al 0,9 % a razón de 1 ml por punto gatillo. A los tres grupos se les evaluó arcos de movilidad, fuerza muscular, intensidad del dolor con la EVA, número de puntos gatillo e índice de discapacidad del cuello al inicio del tratamiento y a las 6 semanas.  Resultados:  Se observó una disminución del dolor y del número de puntos gatillo en los 3 grupos, sin embargo solo fue estadísticamente significativa en el grupo tratado con medicamentos antihomotóxicos.  Conclusiones:  El uso de medicamentos antihomotóxcos aplicados mediante inyección intramuscular en los puntos gatillo puede ser una opción de tratamiento eficaz en pacientes con síndrome doloroso miofascial cervical.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Myofascial pain syndrome is a common cause of muscle pain in cervical region and shoulder girdle. Treatment has included conservative means and invasive procedures; conservative means include drugs, modalities of physical therapy, massage and therapeutic exercise; Invasive procedures include dry nedling and trigger point injections of various substances such as botulinum toxin type A, steroids and local anesthetics and even has been reported effective with the injection of complex homeopathic medicines known as antihomotoxic drugs.  Objective:  To compare the effectiveness of the intramuscular injections in trigger points using a Botulinum toxin type A versus antihomotóxic drugs.  Materials and methods:  We conducted a pilot study, longitudinal, prospective, randomized and blind, type controlled clinical trial, which included 31 patients with diagnosis of myofascial syndrome of cervical region and shoulder girdle, divided in 3 groups; each group received intramuscular injections in trigger points. One group was treated with botulinum toxin type A with a dose of 10U by trigger point, another group was treated with a combination of antihomotoxic drugs that included a mixture of Traumeel(r) S, Spascupreel(r), Gels Homaccord(r) y Lymphomyosot(r) at a rate of 1 ml of this combination by trigger point; the third group received placebo treatment with saline solution at 0.9 % at the rate of 1 ml. for trigger point. The three groups were evaluated mobility, muscular strength, pain intensity with EVA, number of trigger points and disability index of the neck at the start of treatment and at 6 weeks. Results: It was observed a decrease of pain and the number of trigger points in the 3 groups, however it was only statistically significant in the group treated with antihomotoxic drugs.  Conclusions:  The use of antihomotoxic drugs applied by intramuscular injection in the trigger points can be an effective treatment option in patients with cervical myofascial pain syndrome.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Myofascial pain]]></kwd>
<kwd lng="en"><![CDATA[antihomotoxic medicine]]></kwd>
<kwd lng="en"><![CDATA[botulinum toxin type A]]></kwd>
<kwd lng="es"><![CDATA[Dolor miofascial]]></kwd>
<kwd lng="es"><![CDATA[medicamentos antihomotóxicos]]></kwd>
<kwd lng="es"><![CDATA[toxina botulínica tipo A]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Muscle pain syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Phys Med Rehabil]]></source>
<year>2007</year>
<volume>86</volume>
<numero>1 Suppl</numero>
<issue>1 Suppl</issue>
<page-range>S47-58</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myofascial trigger points then and now a historical and scientific perspective]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Thaker]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Heimur]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aredo]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Sikdar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gerber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[PM R]]></source>
<year>2015</year>
<volume>7</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>746-61</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of myofascial pain in general internal medicine practice]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skootsky]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Jaeger]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Oye]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<source><![CDATA[West J Med]]></source>
<year>1989</year>
<volume>151</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>157-60</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myofascial pain syndrome associated with trigger points a literature review: Epidemiology, clinical treatment and etiopathogeny Med Oral Patol Oral Cir]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vázquez-Delgado]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cascos-Romero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gay-Escoda]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Bucal]]></source>
<year>2009</year>
<volume>14</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>e494-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The myofascial trigger point region correlation between the degree of irritability and the prevalence of endplate noise]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuan]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Yen]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[CZ]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J of Phys Med Rehabil]]></source>
<year>2007</year>
<volume>86</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>183-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myofascial trigger points are very prevalent in patients with chronic tension-type headache a double-blinded controlled study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Couppé]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Torelli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fuglsang-Frederiksen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Pain]]></source>
<year>2007</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Annaswamy]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[de Luigi]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging concepts in the treatment of myofascial pain a review of medications, modalities, and needle-based interventions]]></article-title>
<collab>O'Neill BJ.Keole N.Berbrayer D</collab>
<source><![CDATA[PM R]]></source>
<year>2011</year>
<volume>3</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>940-61</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Generalised and regional soft tissue pain syndromes The role of physical and rehabilitation medicine physicians. The european perspective based on the best evidence. A paper by the UEMS-PRM Section Professional Practice Committee]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oral]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ilieva]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Küçükdeveci]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Varela]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Valero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Berteanu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Phys Rehabil Med]]></source>
<year>2013</year>
<volume>49</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>535-49</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The kinesio taping method for myofascial pain control]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[CZ]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
</person-group>
<source><![CDATA[Evid Based Complement Alternat Med]]></source>
<year>2015</year>
<volume>2015</volume>
<page-range>950519</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Needling therapies in the management of myofascial trigger point pain a systematic review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cummings]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Phys Med Rehabil]]></source>
<year>2001</year>
<volume>82</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>986-92</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dry needling in the management of musculoskeletal pain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalichman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vulfsons]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Board Fam Med]]></source>
<year>2010</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>640-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graboski]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Burnham]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain]]></source>
<year>2005</year>
<volume>118</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>170-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porta]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain]]></source>
<year>2000</year>
<volume>85</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>101-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of botulinum toxin in the treatment of chronic myofascial pain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Andrés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cerda-Olmedo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Valía]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Monsalve]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Alarcón]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Minguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Pain]]></source>
<year>2003</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>269-75</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evidence for antinociceptive activity of Botulinum toxin type A in pain management]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aoki]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<source><![CDATA[Headache]]></source>
<year>2003</year>
<volume>43</volume>
<numero>suppl1</numero>
<issue>suppl1</issue>
<page-range>S9-S15</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A double blind, controlled study of Botulinum toxin A in chronic miofascial pain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qerama]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fuglsang-Frederiksen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kasch]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bach]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2006</year>
<volume>67</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>241-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of small doses of botulinum toxin a on neck-shoulder pain syndrome a double blind, randomized, and controlled crossover trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ojala]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Arokoski]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Partanen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Pain]]></source>
<year>2006</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>90-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tratamiento del síndrome de dolor miofascial con toxina botulínica tipo A]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Canovas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[García-Rojo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Morillas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Salgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Pombo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2006</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>96-102</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Therapeutic use of botulinum toxin type a in treating neck and upper-back pain of myofascial origin a pilot study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lew]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Castaneda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Klima]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Date]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Phys Med Rehabil]]></source>
<year>2008</year>
<volume>89</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-80</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Toxina botulínica tipo A para el manejo del dolor en pacientes con síndrome de dolor miofascial crónico]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres-Huerta]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Santos]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz-Ramírez]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Tenopala-Villegas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2010</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Botulinum toxin for myofascial pain syndromes in adults]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andriolo]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Atallah]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[da Silva]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2014</year>
<numero>7</numero>
<issue>7</issue>
<page-range>CD007533</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An update on botulinum toxin A injections of trigger points for myofascial pain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Pain Headache Rep]]></source>
<year>2014</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>386</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A critical appraisal of the evidence for botulinum toxin type A in the treatment for cervico-thoracic myofascial pain syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shkolnikova]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Inwald]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain Pract]]></source>
<year>2014</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>185-95</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tratamiento de las enfermedades músculo-esqueléticas]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Biomedical Res Ther (Heel)]]></source>
<year>2004</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>53-60</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pain management Protocols]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biomed Ther]]></source>
<year>2004</year>
<volume>2</volume>
<page-range>5-7</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Biopuncture Protocols for the Treatment of Chronic Inflammatory Disorders]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kersschot]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biomed Ther]]></source>
<year>2008</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>10-2</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inhibition of IL-1b and TNF-a secretion from resting and activated human immunocytes by the homeopathic medication Traumeel S]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porozov]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cahalonb]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Weiserc]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Branskid]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liderb]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Oberbauma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Dev Immunol]]></source>
<year>2004</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>143-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The homeopathic preparation Traumeel S(r) compared with NSAIDS for symptomatic treatment of epicondylitis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birnesser]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Oberbaum]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kein]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Weisner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Musculoskelet Res]]></source>
<year>2004</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>119-28</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of Spascupreel versus hyoscine butylbromide for gastrointestinal cramps in children]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muller-Krampe]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Oberbaum]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dipl-Math]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Weiser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Int]]></source>
<year>2007</year>
<volume>49</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>328-34</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Multicomponent Medication Lymphomyosot Improves the Outcome of Experimental Lymphedema]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keim]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Slis]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Mendez]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Stroup]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Burmeister]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tsolaki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Lymphat Res Biol]]></source>
<year>2013</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>81-92</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tratamiento con farmacología antihomotóxica de los síntomas asociados a fibromialgia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egocheaga]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[del Valle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2004</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Homotoxicology a review of randomised clinical trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2004</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>299-306</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daza-Lesmes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación clínico funcional del movimiento corporal humano]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Validación de una versión española del Índice de Discapacidad Cervical]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrade-Ortega]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado-Martínez]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Almécija-Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2008</year>
<volume>130</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>85-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Desarrollo de miastenia gravis tras administración de toxina botulínica en el síndrome de dolor miofascial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz-Velázquez]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Zueras-Batista]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Abalo-Delgado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rincón-Vázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana-Gordon]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2015</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>102-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
